Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

被引:395
作者
Bulliard, Yannick [1 ]
Jolicoeur, Rose [2 ]
Windman, Maurice [2 ]
Rue, Sarah M. [3 ]
Ettenberg, Seth [1 ]
Knee, Deborah A. [3 ]
Wilson, Nicholas S. [1 ]
Dranoff, Glenn [4 ,5 ,6 ]
Brogdon, Jennifer L. [1 ]
机构
[1] Novartis Inst Biomed Res, Dept Oncol, Cambridge, MA 02139 USA
[2] Novartis Inst Biomed Res, Lab Anim Serv, Cambridge, MA 02139 USA
[3] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA
[6] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA
关键词
ANTI-GITR MAB; REGULATORY T; MONOCLONAL-ANTIBODY; TUMOR-IMMUNITY; BINDING; CELLS; COSTIMULATION; RESPONSES; MELANOMA; RIII;
D O I
10.1084/jem.20130573
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fc gamma receptor (Fc gamma R) coengagement can facilitate antibody-mediated receptor activation in target cells. In particular, agonistic antibodies that target tumor necrosis factor receptor (TNFR) family members have shown dependence on expression of the inhibitory Fc gamma R, Fc gamma RIIB. It remains unclear if engagement of Fc gamma RIIB also extends to the activities of antibodies targeting immunoregulatory TNFRs expressed by T cells. We have explored the requirement for activating and inhibitory Fc gamma Rs for the antitumor effects of antibodies targeting the TNFR glucocorticoid-induced TNFR-related protein (GITR; TNFRSF18; CD357) expressed on activated and regulatory T cells (T reg cells). We found that although Fc gamma RIIB was dispensable for the in vivo efficacy of anti-GITR antibodies, in contrast, activating Fc gamma Rs were essential. Surprisingly, the dependence on activating Fc gamma Rs extended to an antibody targeting the non-TNFR receptor CTLA-4 (CD152) that acts as a negative regulator of T cell immunity. We define a common mechanism that correlated with tumor efficacy, whereby antibodies that coengaged activating Fc gamma Rs expressed by tumor-associated leukocytes facilitated the selective elimination of intratumoral T cell populations, particularly T reg cells. These findings may have broad implications for antibody engineering efforts aimed at enhancing the therapeutic activity of immunomodulatory antibodies.
引用
收藏
页码:1685 / 1693
页数:9
相关论文
共 33 条
[11]   Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells [J].
Ko, K ;
Yamazaki, S ;
Nakamura, K ;
Nishioka, T ;
Hirota, K ;
Yamaguchi, T ;
Shimizu, J ;
Nomura, T ;
Chiba, T ;
Sakaguchi, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :885-891
[12]   Enhancement of antitumor immunity by CTLA-4 blockade [J].
Leach, DR ;
Krummel, MF ;
Allison, JP .
SCIENCE, 1996, 271 (5256) :1734-1736
[13]   DIFFERENTIAL RESPONSES OF HUMAN TUMOR-CELL LINES TO ANTI-P185(HER2) MONOCLONAL-ANTIBODIES [J].
LEWIS, GD ;
FIGARI, I ;
FENDLY, B ;
WONG, WL ;
CARTER, P ;
GORMAN, C ;
SHEPARD, HM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 37 (04) :255-263
[14]   A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies [J].
Li, Fubin ;
Ravetch, Jeffrey V. .
CELL CYCLE, 2012, 11 (18) :3343-+
[15]   Cancer immunotherapy comes of age [J].
Mellman, Ira ;
Coukos, George ;
Dranoff, Glenn .
NATURE, 2011, 480 (7378) :480-489
[16]   Divergent immunoglobulin G subclass activity through selective Fc receptor binding [J].
Nimmerjahn, F ;
Ravetch, JV .
SCIENCE, 2005, 310 (5753) :1510-1512
[17]   Fcγ receptors as regulators of immune responses [J].
Nimmerjahn, Falk ;
Ravetch, Jeffrey V. .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (01) :34-47
[18]  
Nimmerjahn Falk, 2012, Cancer Immun, V12, P13
[19]   Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density [J].
Niwa, R ;
Sakurada, M ;
Kobayashi, Y ;
Uehara, A ;
Matsushima, K ;
Ueda, R ;
Nakamura, K ;
Shitara, K .
CLINICAL CANCER RESEARCH, 2005, 11 (06) :2327-2336
[20]   Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties [J].
Nordstrom, Jeffrey L. ;
Gorlatov, Sergey ;
Zhang, Wenjun ;
Yang, Yinhua ;
Huang, Ling ;
Burke, Steve ;
Li, Hua ;
Ciccarone, Valentina ;
Zhang, Tengfei ;
Stavenhagen, Jeffrey ;
Koenig, Scott ;
Stewart, Stanford J. ;
Moore, Paul A. ;
Johnson, Syd ;
Bonvini, Ezio .
BREAST CANCER RESEARCH, 2011, 13 (06)